Abstract
Summary
In hypertensive patients Veriloid is an active hypotensive agent when administered acutely, or chronically for periods as long as 5 months. Meticulous regulation of dosage is important in obtaining optimum results. After several weeks of continuous therapy it is frequently necessary to reduce the dosage in order to avoid nausea and vomiting. Nevertheless, relative to its hypotensive effects Veriloid seems to produce fewer toxic reactions than any other oral preparation of Veratrum viride presently available.
Get full access to this article
View all access options for this article.